Jonathan Siegrist, the Executive Vice President of Research and Development and Chief Technology Officer at QuidelOrtho Corp, has reported significant stock transactions that may impact the company and its stakeholders. The transactions, which occurred on October 15, 2026, include both the acquisition and disposition of shares, reflecting Siegrist's active involvement in the company’s equity structure.
QuidelOrtho Corp, known for its work in the life sciences sector, specializes in in vitro and in vivo diagnostic substances. The company is headquartered in San Diego, California, and operates under the ticker symbol QDEL. Recent filings indicate that QuidelOrtho has undergone a name change from Coronado Topco, Inc. as of January 24, 2022.
According to the recent SEC filing (accession number 0002040321-26-000005), Siegrist acquired 18,657 shares through the release of restricted stock units, which were previously reported. Additionally, he disposed of 6,695 shares to satisfy tax withholding obligations related to these stock units. Following these transactions, Siegrist now holds a total of 32,076 shares of QuidelOrtho common stock.
This update may affect various stakeholders, including shareholders, employees, and competitors in the diagnostics industry. Executive ownership often signals confidence in the company's future, and such transactions can influence market perceptions and employee morale.
Details were not available in the SEC filing regarding any future actions or implications stemming from these transactions.